POTASSIUM CHANNEL PROTEIN KCNQ5, A TARGET FOR DISEASES OF CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR SYSTEM

Abstract: The present invention is related to a DNA sequence coding for a polypeptide having KCNQ5 activity, several polynucleotide sequences related to KCNQ5, and a screening assay for identification of compounds which modify activity of a potassium channel KCNQ5.

Description: POTASSI U M CHANNEL PROTEIN KCNQ5 , A TARGET FOR DISEASES OF CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR SYSTEM The invention is related to a novel potassium channel protein KCNQ5 which is considered as target for diseases of central nervous system and cardiovascular system. The protein is used as screening tool for identification of compounds which improve symptoms of diseases of central nervous system and cardiovascular system. Voltage-dependent potassium channels are key regulators of the resting membrane potential and modulate the excitability of electrically active cells like neurons and cardiac myocytes. Several classes of voltage-dependent K + channels have been cloned and probably all form oligomeric proteins through the assembly of four α- protein subunits. The tetrameric pore complex further can interact with auxiliary subunits that enhance and/or modify currents mediated by the pore-forming α- subunits. The KCNQ family of voltage-dependent K + channels originally was established by positional cloning of the KCNQ1 gene (KvLQTI) which encodes a K + channel protein with six transmembrane domains and a characteristic pore region. So far the KCNQ family consists of four members all of which are associated with human diseases. KCNQ1 functionally interacts with KCNE1 , a small β-subunit protein with a single transmembrane domain, to generate the slowly-activating delayed-rectifier l Ks current of cardiomyocytes. Inactivating mutations in both subunits result in the prolongation of the cardiac action potential and an increased risk of ventricular arrhythmias in patients with long QT-syndrome (LQTS). KCNQ1 and KCNE1 also are found in the inner ear and some loss of function mutations of KCNE1 and KCNQ1 are associated with hearing loss. In intestine KCNQ1 probably associates with the structurally related KCNE3 protein to generate different K + channels. The KCNQ1/KCNE3 channel complex possibly represents the basolateral cAMP 1 -regulated K + conductance in colonic crypts probably important for apical cAMP-stimulated chloride secretion and that is involved in secretory diarrhoea and cystic fibrosis. KCNQ2 and KCNQ3 are expressed in the brain and colocalize in various brain areas (Biervert, C. et al.; Science 279, 403-406, 1998). Whereas KCNQ2 generates K + currents very similar to KCNQ1 (Schroder, B. C. et al.; Nature 396, 687-690, 1998), KCNQ3 alone produces only small currents (Wang, W.-P. et al., J. Biol. Chem. 273, 5 19419-19423, 1998). Coexpression of both KCNQ2 and KCNQ3 resulted in currents that were at least 10-fold larger than that of KCNQ2 alone (Wang, H.-S. et al.; Science 282, 1890-1893, 1998), suggesting that KCNQ3 facilitates expression of KCNQ2 subunits, by formation of a heteromeric complex of KCNQ2 and KCNQ3 subunits. The genes encoding KCNQ2 and KCNQ3 have been cloned due to their 0 linkage to a form of epilepsy in human infants and loss of function mutations have been identified in both genes in patients with benign familial neonatal convulsions (BNFC) (Sigh, N. A. et al.; N. Genet. 18, 25-29, 1998; Chariier, C. et al.; N. Genet. 18, 53-55, 1998)). Since epilepsy is due to an electrical hyperexcitability in the brain, KCNQs may have an important stabilizing role in the nervous system. Biophysical 5 and pharmacological properties of KCNQ2/KCNQ3 currents are very similar to that of the native neuronal M-type K + current that is also characterized by muscarinic modulation and that is thought to be a prominent regulator of neuronal excitability as well. Similar to the native M-current, KCNQ2/KCNQ3 channel activity is strongly reduced by muscarinic acetylcholine agonists and therefore it is now assumed that 0 KCNQ2 and KCNQ3 subunits contribute to the native M-channel. KCNQ4, another member of this gene family, is expressed in sensory outer hair cells of the cochlea and is mutated in dominant deafness. Interestingly, coexpression of KCNQ3 with KCNQ4 also increased current amplitudes, although to a far less extent than observed with KCNQ2/KCNQ3 coexpression. This raises the possibility that 5 different KCNQ channels can combine to produce variants of M-currents in different parts of the nervous system. Problem of the invention was to identify another gene member of the KCNQ family including the protein for use as a target for treatment of various diseases. 0 KCNQ5 produces K + channels that are activated by depolarization and that are very similar to the currents generated by other KCNQ channels. KCNQ5 is expressed in skeletal muscle and in the brain, where its expression pattern overlaps with that of KCNQ2 and KCNQ3 that underlie the native M-current. Similar to KCNQ2, KCNQ5 forms functional heteromers with KCNQ3, suggesting that neuronal M-channels probably can also include KCNQ5 subunits. The subject matter of this invention is related to a DNA sequence coding for a polypeptide having KCNQ5 activity said polypeptide being selected from the following group: a) a polypeptide having the aminoacid sequence of a potassium channel KCNQ5, b) a polyeptide having the aminoacid sequence of SEQ ID No 2, c) a polypeptide which in respect to b) is deficient in one or more aminoacids or d) polypeptide which in respect to b) has one or more aminoacids replaced. This invention is further related to a DNA sequence wherein the DNA sequence has been selected from at least one of the following group of polynucleotide sequences: a) a polynucleotide having the polynucleotide sequence of Seq ID No 1 , b) a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide sequence according to a), c) a polynucleotide which hybridizes under low or medium stringency conditions to a polynucleotide sequence according to a), d) a polynucleotide sequence complementary to a polynucleotide sequence as defined in one of a), b), or c). The DNA sequence as mentioned above can be part of the genome of each organism which harbors a gene for KCNQ5. In particular the DNA sequence is part of a mammal or a human being. Preferred species amongst the mammals for the purpose of the invention are mouse and rat. The invention refers further to a recombinant DNA vector, said vector comprisinga polynucleotide element which renders the vector suitable for its multiplication in procaryotic or eucaryotic cells and a DNA sequence as aforementioned coding for the amino acid sequence or a polynucleotide sequence for KCNQ5. This DNA element which renders the vector suitable for mulitiplication can be a origin of replication which works in procaryotiy or eucaryotic cells. An example for an origin of replication which works in procaryotic cells is the colE1 oh. A recombinant vector needs further a selection marker for control of growth of these organisms which harbor the vector. As selection markers suitable are genes which protect organism from antibiotics (antibioticum resistance) e.g. ampicillin, streptomycin, chloramphenicol or provide growth under compound deprived environmental conditions (auxotrophic growth conditions) when expressed as proteins in cells. In a preferred embodiment of the invention for multiplication of the said recombinant vector the procaryotic cells are bacteria. In special preferred versions of the inventions he bacteria are in particular bacteria of Escherichia coli or of Bacillus spec. In a further preferred embodiment of the invention for the multiplication of the said recombinant vector the eucaroytic cells are cells of a cell line or yeast cells. In special preferred versions of the invention the cells of the cell line are cells of a COS, Hela-, or 3T3-cell-line and the yeast cells are cells of Saccharomyces cerevisiae. The said recombinant DNA could provide for a promotor element which is operationally linked to a DNA sequence coding for the amino acid sequence or polynucleotide sequence of a kCNQ5 allowing transcription of the related RNA and/or expression of the related protein. This promotor element an be taken in preferred versions of the invention from procaryotic promotors or eucaryotic promotors. A procaryotic is characterized by its ability to induce transcription in procaryotic organisms as a eucaryotic promotor is characterized by its ability to induce transcription in eucaryotic organisms. Both procaryotic and eucaryotic promotor element can be preferred incucible promotors or further preferred constitutive promotors. An inducible promotor is switched on only when a signal event is present. The signal can be born by the organisms metabolism. Then it often consists of metabolic products, hormones, degradation products of macromolecules or other metabolic derived substances. The signal can also be provided by the environment. Then it may consist of radiation, temperature or chemical compounds of the environment. A constitutive promotor needs no induction for activity. The invention includes further a host cell this host cell comprising at least one recombinant DNA vector as mentioned before. The host cell is taken preferred from procaryotic or eucaryotic cells. When it is taken from procaryotic cells it preferably consists of a cell of a bacterium in particular of Escherichia coli or Bacillus spec. When this host cell consists of a eucaryotic cell it is preferred a cell of a cell line in particular a cell of a COS-, a Hela-, or 3T3-cell-line or a cell of a yeast in particular a cell of Saccaromyces cerevisiae. This host cell can be produced by transforming the said host cell by a recombinant DNA vector comprising a DNA sequence coding for a amino acid sequence or polynucleotide sequence of a KCNQ5. The transformation can take place by routine methods used in microbiology as for example transformation of competent cells , Ca2 + -phosphate-precipitation or electroporation. The invention refers also to a protein encoded by one of the DNA sequences as aforementioned. This protein has activity of a KCNQ5. Activity of KCNQ5 is characterized by ion transport of this transporter type. Further included is production of a protein wherein first a host cell harboring a recombinant vector including a DNA sequence encoding for an amino acid sequence or a polynucleotide sequence for KCNQ5 is propagated in a suitable growth medium chosen from either media for bacteria or eucaryotic cells in dependance of the related cell type. This propagated cells are second harvested by common methods of biochemistry as centrifugation or filtration and processed to obtain crude cell extracts. These cell extracts third are purified subsequently by methods used for protein purification as size exchange chromatography, ion exhange chromatography, affinity chromatography and others to gain the protein of interest (KCNQ5) separated from other compounds of the cell lysates. The invention includes further a process for identification of a compound which compound is suitable for modification of activity of a protein having activity of KCNQ5 as mentioned before comprising a) Providing of KCNQ5 or a protein having activity of KCNQ5 b) Providing of at least one chemical compound; c) Incubating the chemical compound according to b) with a protein accoding to a); d) Measuring activity of protein accoding to a). In a preferred embodiment of the invention the protein having activity of KCNQ5 as claimed from a) is provided within a host cell as aforementioned. The KCNQ5 may interact with other proteins for the purpose of this invenetion in a further preferred version of the invention. In particular it interacts with KCNQ3. Such a screening assay is applicable for identification of at least one chemical compound which modifies activity of KCNQ5 and which has impact on diseases of central nervous system or cardiovascular system. This invention further refers to a method for detection of a protein as claimed having activity of KCNQ5 comprising the following steps: a) providing biological material; b) incubating the biological material with a compound which modifies activity of a protein having activity of KCNQ5 and if required for reference purposes with a compound which does not modify activity of KCNQ5; c) measuring activity of a protein having activity of KCNQ5 after incubating the biological material with a chemical compound according to b). Further included within this invention is a test kit comprising different parts in particular a chemical compound which is suitable of modifying the activity of KCNQ5. Such a chemical compound which is applicable as part of this test kit for modification of a protein having activity of KCNQ5 may be identified according to a method as aforementioned. Example: Example 1 : Molecular Cloning and Expression of KCNQ5 KCNQ5 a novel member of the KCNQ family of potassium channels was isolated. The gene is expressed in different regions of the brain and in skeletal muscle. When expressed in Xenopus oocytes KCNQ5 alone generates voltage-dependent, slowly activating K + -selective currents that are insensitive to the K + channel blocker TEA and display a marked inward rectification at positive membrane voltages. Upon coexpression with the related KCNQ3 channel amplitude of the K + current is increased 4-5 fold. Compared to homomeric KCNQ5 currents, KCNQ3/KCNQ5 heteromeric currents also display slower activation and less inward rectification, showing that KCNQ5 combines with KCNQ3 to form functional channel proteins. The functional interaction between KCNQ5 and KCNQ3, a known protein subunit of the neuronal M-current, suggests that KCNQ5 possibly can contribute to native neuronal M-like currents. The KCNQ5 gene was initially identified as a genomic survey sequence (BAC clone) in a homology search of GenBank (accession number AQ344243). Using this sequence a human brain cDNA library (available from Edge BioSystems) was screened. A composite full-length cDNA construct was assembled from two overlapping cDNA clones and subcloned into the Xenopus expression vector pSGEM (Villmann, C. et al.; J. Neurosci. 17, 7634-7643). The cDNA was fully sequenced on both strands using an automated DNA sequencer (ABI 310). For Xenopus oocyte expression capped cRNA was synthesized using the T7 mMessage mMachine kit (AMBION). For northern blot analysis a DIG-labeled riboprobe of 1.6 kb in length (containing mainly C-terminal sequences) was generated with the DIG RNA Labeling kit (available from ROCHE Diagnostics) according to the manufacturers instructions and hybridized to a series of human RNA blots (available from CLONTECH). Example 2: Chromosomal Localization of KCNQ5 Fluorescence In Situ Hybridization (available from FISH, Genome Systems) analysis was performed to determine the chromosomal localization of KCNQ5. Briefly, purified DNA from the BAC clone (AQ344243) was labeled with digoxigenin dUTP by nick translation and the labeled probe was hybridized to human metaphase chromosomes derived from PHA stimulated peripheral blood lymphocytes. KCNQ5-specific signals were detected on the long arm of chromosome 6 (6q14) using fluoresceinated antidigoxigenin antibodies followed by counterstaining with DAPI and confirmed by cohybridization with a genomic clone previously mapped to 6p21. Example 3: Electrophysiology Xenopus laevis oocytes were obtained from tricaine anaesthetized animals. Ovaries were coJlagenase treated (1 mg/ 1 ml, Worthington, type II) in OR 2 solution (NaCI 82.5 mM, KCI 2 mM, MgCI 2 1 mM, HEPES 5 mM, pH 7.4) for 120 min and subsequently stored in recording solution ND-96 (NaCI 96 mM, KCI 2 mM, CaCI 2 1.8 mM, MgCI 2 1 mM, HEPES 5 mM, pH 7.4) with additional NaPyruvate (275 mg/l), Theophylline (90 mg/l) and Gentamycin (50 mg/l) at 18°C. Oocytes were individually injected with 10 ng cRNA encoding hKCNQδ, rKCNQ3 (GenBank accession number AF087454), hKCNQ2, and hKCNQI , respectively, or coinjected with 10 ng hKCNQδ plus 5 ng hlsk (KCNE1 ), hMiRPI (KCNE2), hMiRP2 (KCNE3), mMiRP3 (KCNE4), respectively. rKCNQ3 was cloned from a λZAP cDNA library (STRATAGENE) using an DIG-labeled (ROCHE) EST-clone (GenBank accession number AA019129) as a probe. hMiRPI and hMiRP2 were cloned from human genomic DNA, mMiRP3 from murine brain cDNA using primers derived from the published sequences (13). Standard two-electrode voltage-clamp recordings were performed at room temperature with a Turbo Tec 10CD (NPI) amplifier, an ITC-16 interface combined with Pulse software (HEKA) and Origin for data aquisition on Pentium II PC. Macroscopic currents were recorded 2-4 days after injection. All fitting procedures were based on the simplex algorithm. Student ' s t test was used to test for statistical significance, which was assumed if P<0.05 and indicated by * . Example 4: Cloning and Tissue distribution of KCNQ5 Search of the GenBank data base revealed a human BAC end sequence (AQ344243) with significant homology to the KCNQ K + channel family. The sequence information was used to isolate overlapping cDNA clones from a human brain cDNA library (Edge Biosystems) and two cDNA clones were assembled to generate a full- length cDNA clone. The initiator methionine of the cDNA was assigned to the first ATG in frame, and is preceded by a stop codon in the same frame. The full-length KCNQ5 cDNA encodes a polypeptide of 932 amino acids (Fig. 1 A) with a predicted molecular mass of «102 kDa. Hydropathy analysis supports the topology model with six transmembrane domains. KCNQ5 shows significant homology to other KCNQ proteins, with KCNQ4 being the closest relative (65% identity). KCNQ5 is about 50% identical to KCNQ3 and KCNQ2 but only 40% to KCNQ1 (Fig. 1 B). Homology is observed in particular throughout the membrane spanning regions and the conserved P-loop between transmembrane segments S5 and S6. KCNQ proteins are characterized by their very long C-terminal tails. KCNQ5 has the longest C-terminus of all KCNQ proteins followed by KCNQ2 and KCNQ3. It contains a highly conserved region the function of which is still not known, but that is frequently mutated in other KCNQ proteins. Furthermore, in a BNFC family, a frame shift mutation at the nonconserved 3 ' end produces a mutant KCNQ2 protein with 56 additional amino acids at its C-terminus. Surprisingly, the currents generated in oocytes by the larger mutant protein were reduced by 50% compared to the wild-type. Further, introducing a stop mutation at the very same position, which truncated the last seven amino acids, increased channel activity twofold. Together these results show that the C- terminal region of KCNQ proteins is important for channel function. The KCNQ5 protein contains numerous potential sites for phosphorylation by PKC, but lacks a N-terminal consensus site for cAMP-dependent phosphorylation that is present in KCNQ1 and KCNQ2. KCNQ1 as well as l s currents were stimulated by PKA, whereas conflicting data have been reported concerning the effect of PKA on KCNQ2 currents. Northern blot analyses detected 7.5 kb large KCNQ5 transcripts in human skeletal muscle and brain. In the brain transcripts are widely distributed with strongest expression in cerebral cortex, occipital pole, frontal lobe, and temporal lobe. Lower levels were detected in hippocampus and putamen. The expression pattern of KCNQ5 in the brain is very similar to that previously described for KCNQ2 and KCNQ3 that have transcripts sizes of 8.5 kb and 10.5 kb, respectively. In contrast to KCNQ2, KCNQ5 probably is absent in cerebellum. Example 5: Expression of KCNQ5 in Xenopus oocytes The possible function of KCNQ5 as a potassium channel was addressed by electrophysiological analysis of Xenopus oocytes injected with KCNQ5 cRNA transcribed in vitro. Two to four days after injection novel currents were detected that were not observed in water-injected control oocytes. Currents activated very slowly (Fig. 3A) and were not fully activated even within 2 seconds. At lower potentials KCNQ5 currents show a delay in activation, similar to KCNQ1 currents. Activation traces above +20 mV display a cross-over phenomenon. Activation of KCNQ5 currents is generally slower than that of other KCNQ currents. However, it can be described by a biexponential function. During a depolarizing pulse from -100 to +40 mV, current was activated with time constants of 116 ± 7, and 927 ± 51 ms (Tablel ). Current-voltage relations of KCNQ5 currents are shown in Fig. 3B. Currents activated at depolarizing potentials positive to -60 mV and markedly inwardly rectified at potentials greater than 0 mV. Strong inward rectification only has been demonstrated for the related KCNQ3 channels. KCNQ5 deactivation was well fitted to a second order exponential function. The two components of deactivation were determined at a repolarizing voltage of -100 mV following a 3s depolarizing step to +40 mV. Time constants were 64 ± 5 and 269 ± 24 ms (Tablel ). KCNQ1 tail currents display a characteristic „hook" indicative of recovery from inactivation. We did not observe such a feature at voltages between -100 and +40 mV. Additionally, a a double-pulse protocol was performed which is commonly used to reveal inactivation of potassium currents. To examine the K + selectivity of KCNQ5 currents tail current reversal potentials were determined in bath solutions containing 5.4, 9.6, 20, 54 and 96 mM K + . A tenfold reduction in external K + shifted the reversal potential by 58 mV (Fig. 3C), indicating that KCNQ5 is perfectly selective for K + . Pharmacological properties of KCNQ5 are shown in Fig. 3D. KCNQ5 currents were insensitive to the nonselective K + channel blocker TEA, as reported for KCNQ3. Consistently, both channel proteins contain threonine residues within the pore region at a position that determines sensitivity to blockade by TEA. In contrast, a tyrosine residue at this position is responsible for the high sensitivity of KCNQ2 to TEA. The unspecific ion channel blocker quinidine at 300 μM blocks KCNQ5 currents by 50%. Inhibitors of KCNQ1 and l Ks were tested at concentrations that completely or strongly block these currents. From those the chromanol 293B was the most effective one, but at 100 μM it blocked KCNQ5 currents only by 45%. In comparison, at this concentration KCNQ1 is blocked by 80%. Clofilium is a class III antiarrhythmic agent and blocks KCNQ1 with an IC 50 <10 μM. At 30 μM it reduced KCNQ5 current by 40%, similar to its inhibitory effect on KCNQ3 (30% inhibition at 10μM). Clofilium produced little inhibition of KCNQ2 at 10μM. Thus, pharmacological properties of KCNQ5 are more similar to that of KCNQ3 than to KCNQ2. Example 6: Functional Interaction of KCNQ5 and KCNQ3 All members of the KCNQ family form functional heteromers with homologous or structurally different K + channel subunits. To investigate the possibility that KCNQ5 might also form mixed channels with a different protein subunit, we coexpressed in Xenopus oocytes KCNQ5 with other KCNQ proteins and with cDNAs encoding different KCNE polypeptides. After coexpression with either KCNQ1 or KCNQ2, or with one of the four known KCNE peptides (KCNE1 through KCNE4), we did not observe any evidence for functional interaction of one of those proteins with KCNQ5. However, coexpression of KCNQ5 with KCNQ3 strikingly changed resulting currents. Whereas KCNQ3 alone generated only very small currents almost indistinguishable from background level in agreement with previous findings, coinjection with KCNQ5 increased currents about 4-5 times compared with KCNQ5 alone. There was no significant shift in the voltage dependency of the currents but the l-V relationship shows that KCNQ5/KCNQ3 currents were less inwardly rectifying at positive membrane potentials. Increase in current amplitude also was accompanied by changes in gating kinetics, as shown in Table 1. Incorporation of KCNQ3 significantly slowed the fast component of activation but did not alter the slow component. Moreover, fast deactivation of KCNQ5/KCNQ3 currents was slowed compared to homomehc KCNQ5. In addition to a large increase in current amplitude, association of KCNQ2 and KCNQ3 also reportedly changed gating properties of the resulting heteromeric currents. Therefore, we investigated the gating kinetics of the KCNQ2/KCNQ3 current and compared it with KCNQ5/KCNQ3 (Table 1). In KCNQ2/KCNQ3 both fast and slow time constants of activation were slowed, as was the fast component of deactivation. Thus, while KCNQ2/KCNQ3 heteromers still activate faster than KCNQ3/KCNQ5 heteromers, deactivation kinetics of both heteromers were not significantly different. The colocalization of KCNQ5 with KCNQ3 in various parts of the brain, the large increase in currents, and the differences in gating kinetics observed after coexpression strongly indicate that KCNQ5 can associate with KCNQ3 to form functional channels. Since KCNQ2/KCNQ3 channels are believed to constitute the molecular basis of the neuronal M-current, our results further suggest that KCNQ5 may also be a subunit of this physiologically important current. The M-current is expressed in peripheral and central neurons, but has not been described in the cerebellum. Consistently, KCNQ3 and KCNQ5 are only weakly or not expressed in this region, in contrast to KCNQ2 which curiously is strongly expressed in cerebellum. KCNQ4 also can functionally interact with KCNQ3 to yield M-like currents, raising the possibility that heterogenous populations of M-currents exist within the peripheral and central nervous system that probably vary in their kinetic and pharmacological properties. Heterogeneity in the molecular composition of M-like channels may even be increased by contribution of K + channels from other families. The possibility that the KCNQ5 protein can contribute to M-currents within the brain renders the KCNQ5 gene a putative candidate for epileptic disease. By fluorescent in situ hybridization (FISH) analysis we mapped the KCNQ5 gene to chromosome 6q14. There are two loci on chromosome 6 that were linked to epileptic diseases, a known gene on 6q24, which is defect in progressive myoclonic epilepsy type 2, and an unknown gene on 6p12-p11 , which is responsible for juvenile myoclonic epilepsy (EJM1). However, our mapping results exclude involvement of KCNQ5 in the latter disease. The identification of KCNQ5 makes it now possible to investigate a possible association with other forms of genetically inherited epilepsy. For the methods used within the scope of this invention reference is made to "Current protocols of Molecular Biology; eds.: Ausubel F. M. et al.; Wiley Interscience, New York ; 2000 (currently updated)" concerning Molecular Biology and to "Experimental Biochemistry; eds.: Switzer, R. L. et al. W. H. Freeman & Co 1999" concerning Biochemistry. In the invention , a novel member of the KCNQ family was cloned and identified. The abbreviations used are: cAMP, cyclic 5 ' -adenosine monophosphate; DIG, digoxigenin; GCG, Genetics Computer Group, Wisconsin package version 10; Iks, slow component of the cardiac delayed rectifier current; kb, kilobase; KCNQ, potassium channel of the KCNQ gene family; PHA, phytohemagglutinin; PKA, proteine kinase A; SEM, standard error of the mean; TEA, tetraethylammonium. Description of figures Fig.lA: Protein sequence of KCNQ5 and comparison with other KCNQ proteins. A, alignment of human KCNQ5 with human KCNQ1 , KCNQ2, KCNQ3 and KCNQ4. Identical and conserved amino acids are boxed in black and grey, respectively. The six putative transmembrane domains S1 through S6 and the pore region H5 are indicated by the stipled lines. The KCNQ5 sequence has been deposited in the EMBL/GenBank database. Fig. 1 B: dendrogramm of the human KCNQ proteins, generated with the Pileup programm of the GCG software package. Fig. 2: Tissue distribution of human potassium channel KCNQ5. A multiple tissue Northern blot and two blots from different parts of human brain containing poly(A) + RNA (Clontech) were hybridized with a KCNQ5-specific DIG-labeled RNA probe. Fig. 3: Functional expression of KCNQ5 in Xenopus oocytes. A, representative current traces from a KCNQ5 injected oocyte subjected to a pulse protocol that stepped the membrane potential from holding potential (-100 mV) to test pulses from -100 to + 50 mV and back to holding potential. B, l-V relationships for KCNQ5 expressing oocytes (n=12) recorded using the protocol in A. C, tail current reversal potential of KCNQ5 currents as a function of extracellular K + concentration. The dashed line is drawn according to the Nernst equation for a perfectly selective K + channel (n=5). D, effects of TEA, clofilium, quinidine, and chromanol 293B on KCNQ5 current. Superimposed currents were obtained during a 3s depolarizing step from -100 mV to 0 mV, during the same experiment. Between compounds oocytes were perfused with ND96 until complete reversal of effects (current traces are normalized to control and averaged from 5 oocytes). Error bars indicate SEM. Fig. 4: Functional interaction of KCNQ5 with KCNQ3. A, representative current traces recorded from an oocyte coinjected with KCNQ5 and KCNQ3 using the same protocol as in Fig. 3A. B, l-V relationships of oocytes expressing KCNQ5 + KCNQ3 (n=11 ). C, bar graphs represent means of current amplitudes at the end of a 3s test pulse from -100 to +40 mV. Oocytes were injected with cRNA encoding KCNQ5 (n=14), KCNQ3 (n=6), or KCNQ5 + KCNQ3 (n=12). Error bars indicate SEM. Fig. 5: Activation and Deactivation time constants of homomeric and heteromeric KCNQ channels. Oocytes were injected with 10 ng of either KCNQ5 or KCNQ2 cRNA, or with a mixture of 10 ng each of KCNQ5 and KCNQ3, or KCNQ2 and KCNQ3 cRNA. Currents were measured and fitted for activation and deactivation time constants as described in the text and in Experimental Procedures, respectively. Asteriks indicate significance. Values are mean ± SEM (averaged from 9-16 oocytes).

Claims: Claims: 1. A DNA sequence coding for a polypeptide having KCNQ5 activity said polypeptide being selected from the following group: a) a polypeptide having the aminoacid sequence of a potassium channel KCNQ5, b) a polyeptide having the aminoacid sequence of SEQ ID No 2, c) a polypeptide which in respect to b) is deficient in one or more aminoacids or d) polypeptide which in respect to b) has one or more aminoacids replaced. 2. A DNA sequence as claimed in claim 1 selected from at least one of the following group of polynucleotide sequences: a) a polynucleotide having the polynucleotide sequence of Seq ID No 1 , b) a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide sequence according to a), c) a polynucleotide which hybridizes under low or medium stringency conditions to a polynucleotide sequence according to a), d) a polynucleotide sequence complementary to a polynucleotide sequence as defined in one of a), b), or c). 3. A DNA sequence as claimed in claim 1 or 2 wherein the DNA sequence is part of a mammal. 4. A DNA sequence as claimed in claim 1 or 2 wherein the DNA sequence is part of a human. 5. A recombinant DNA vector, said vector comprising a) a polynucleotide element which renders the vector suitable for its multiplication in procaryotic or eucaryotic cells b) a DNA sequence as claimed in one of claims 1 to 4. 6. A recombinant DNA vector as claimed in Claim 6 comprising a polynucleotide element which renders the vector suitable for multiplication in procaryotic cells in particular in cells of a bacterium. 7. A recombinant DNA vector as claimed in claim 5 or 6 wherein the cells of a 5 bacterium are cells of Escherichia coli or Bacillus spec. 8. A recombinant DNA vector as claimed in Claim 6 comprising a polynucleotide element which renders the vector suitable for multiplication in eucaryotic cells in particular in cells of a cell line or yeast cells. 10 9. A recombinant DNA vector as claimed in claim 8 wherein the cells of a cell line are cells of a COS-, Hela-, or 3T3-cell-line and the yeast cells are cells of Saccharomyces cerevisiae. 15 10. A recombinant DNA vector as claimed in one of claims 5 to 9 wherein the DNA sequence as claimed in one of claims 1 to 4 is operably linked to a promotor element which allows for transcription of the related RNA and/or expression of the related protein. 20 11.A recombinant DNA vector as claimed in claim 10 wherein the promotor element is a procaryotic promotor. 12. A recombinant DNA vector as claimed in claim 10 wherein the promotor element is an eucaryotic promotor. 25 13. A recombinant DNA vector as claimed in claim 11 or 12 wherein the promotor element is inducible 14. A host cell comprising at least one recombinant DNA vector as claimed in claims 30 5 to 13. 15. A host cell as claimed in claim 14 wherein the host cell is a procaryotic or eucaryotic cell. 16. A host cell as claimed in claim 15 wherein the procaryotic cell is a bacterium in 5 particular a cell of Escherichia coli, Bacillus spec. 17. A host cell as claimed in claim 15 wherein the eucaryotic cell is a cell of a cell line in particular a cell of a COS-, a Hela-, or 3T3-cell-line or a cell of a yeast in particular a cell of Saccaromyces cerevisiae. 10 18. Producing of a host cell as claimed in one of claims 14 - 17 by transforming the said host cell by a recombinant DNA vector as claimed in one of claims 5 to 13. 19. A protein encoded by one of the DNA sequences as claimed in claims 1 to 4. 15 20. Production of a protein as claimed in claim 16 by first growing a host cell as claimed in one of claims 14 to 17, second harvesting and processing the cells and third purifying subsequently the protein. 20 21. A process for identification of a compound which compound is suitable for modification of activity of a protein having activity of KCNQ5 as claimed in one of claims 19 or 20 comprising e) Providing of KCNQ5 or a protein as claimed in claim 19 or 20; f) Providing of at least one chemical compound; 25 g) Incubating the chemical compound according to b) with a protein accoding to a); h) Measuring activity of protein accoding to a). 22. A process as claimed in claim 21 wherein the protein as claimed from a) is provided within a host cell as claimed in one of claims 14 - 17 and said host cell 30 expressed the protein. 23. A process as claimed in claim 21 wherein the protein as claimed from a) is interacting with KCNQ3. 24. A method for detection of a protein having activity of KCNQ5 as claimed in claim 19 or 20 comprising the following steps: d) providing biological material; e) incubating the biological material with a compound which modifies activity of KCNQ5 or a protein as claimed in claim 19 or 20 and if required for reference purposes with a compound which does not modify activity of KCNQ5 or a protein as claimed in claim 19 or 20; f) measuring activity of KCNQ5 or of a protein as claimed in claim 19 or 20 after incubating the biological material with a chemical compound according to b). 25. A test kit comprising different parts in particular a chemical compound which is suitable of modifying the activity of KCNQ5. 26. A chemical compound which is suitable for modification of activity of KCNQ5 or a protein as claimed in one of claims 19 or 20 and which chemical compound has been identified according to one of claims 21 to 23.

Inventors: BUSCH ANDREAS, LERCHE CHRISTIAN, SCHERER CONSTANZE, SEEBOHM GUISCARD, STEINMEYER KLAUS, BUSCH, ANDREAS, LERCHE, CHRISTIAN, SCHERER, CONSTANZE, SEEBOHM, GUISCARD, STEINMEYER, KLAUS
Applicants: AVENTIS PHARMA GMBH, AVENTIS PHARMA DEUTSCHLAND GMBH
Application year: 2001
Main classification: C07K14
IPC codes: C07K14, C12N1, C12N5, C12N15, C12P21, G01N33